Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Toshifumi Yamaguchi"'
Autor:
Dai Okemoto, Toshifumi Yamaguchi, Mariko Yamaguchi, Toru Kadono, Hiroki Yukami, Elham Fakhrejahani, Hiroki Nishikawa
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 1001-1007 (2024)
Introduction: In recent years, trastuzumab and pertuzumab have been used in treatment protocols for patients with HER2-positive colorectal cancer. Although severe thrombocytopenia is an uncommon side effect of anti-HER2 antibody therapy, we present t
Externí odkaz:
https://doaj.org/article/1642784669d742c396cf1d2633a51794
Autor:
Kenro Hirata, Kayo Yoshida, Chikatoshi Katada, Akinori Watanabe, Takahiro Tsushima, Toshifumi Yamaguchi, Sachiko Yamamoto, Hideki Ishikawa, Yasunori Sato, Chiyo K. Imamura, Yusuke Tanigawara, Yoshinori Ito, Ken Kato, Yuko Kitagawa, Yasuo Hamamoto
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background In older patients, esophageal squamous cell carcinoma (ESCC) is difficult to treat using standard therapies, including surgery and cisplatin-based chemoradiotherapy. Paclitaxel (PTX) has radiosensitizing activity. We conducted a p
Externí odkaz:
https://doaj.org/article/09b052b87e8a4618ae3372b67d5b1297
Autor:
Toshifumi Yamaguchi, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Masahiro Goto, Taroh Satoh
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Although docetaxel plus S-1 adjuvant chemotherapy after gastrectomy with D2 lymphadenectomy has been a standard of treatment for stage III gastric cancer, there is no established chemotherapy for patients with recurrence during or
Externí odkaz:
https://doaj.org/article/baaa9aef03d34117ae82f3ae1201ee5a
Autor:
Toshifumi Yamaguchi, Atsuo Takashima, Kengo Nagashima, Koshi Kumagai, Tatsuya Yamada, Masanori Terashima, Hiroshi Yabusaki, Kazuhiro Nishikawa, Kazuaki Tanabe, Gen Yunome, Yasuyuki Kawachi, Takanobu Yamada, Takeo Fukagawa, Takahiro Kinoshita, Masaya Watanabe, Koshiro Ishiyama, Kentaro Inoue, Narikazu Boku
Publikováno v:
Gastric Cancer. 26:307-316
Autor:
Shogen Boku, Hironaga Satake, Takashi Ohta, Seiichiro Mitani, Kentaro Kawakami, Yozo Suzuki, Toshihiko Matsumoto, Tetsuji Terazawa, Eiki Yamazaki, Hiroko Hasegawa, Tatsuki Ikoma, Mamoru Uemura, Toshifumi Yamaguchi, Atsushi Naito, Yasunobu Ishizuka, Yukinori Kurokawa, Daisuke Sakai, Hisato Kawakami, Toshio Shimokawa, Toshimasa Tsujinaka, Takeshi Kato, Taroh Satoh, Yoshinori Kagawa
Publikováno v:
Future Oncology. 18:4153-4160
The BRAF V600E mutation accounts for approximately 5% of colorectal cancer (CRC) cases and is an extremely poor prognostic factor. However, there are no clear recommendations regarding first-line therapy for patients with early recurrent BRAF V600E-m
Autor:
Masahiko Aoki, Shigenori Kadowaki, Naoki Takahashi, Takeshi Suzuki, Kotoe Oshima, Takayuki Ando, Yoshiyuki Yamamoto, Kentaro Kawakami, Yosuke Kito, Toshihiko Matsumoto, Keitaro Shimozaki, Yasuhiro Miyazaki, Toshifumi Yamaguchi, Michitaka Nagase, Takao Tamura, Yusuke Amanuma, Taito Esaki, Yuji Miura, Kohei Akiyoshi, Eishi Baba, Akitaka Makiyama, Yuji Negoro, Koji Nakashima, Naotoshi Sugimoto, Kengo Nagashima, Hirokazu Shoji, Narikazu Boku
Publikováno v:
Gastric Cancer. 26:132-144
Background Accelerated tumor growth during immunotherapy in pre-existing measurable lesions, hyperprogressive disease (HPD), has been reported. However, progression of non-measurable lesions and new lesions are frequently observed in patients with ad
Autor:
Takako, Ikegami, Hiroki, Nishikawa, Masahiro, Goto, Fukutaro, Shimamoto, Tetsuji, Terazawa, Toshifumi, Yamaguchi, Eiki, Yamasaki, Ken, Asaishi, Shiro, Nakamura, Kazuhide, Higuchi
Publikováno v:
Journal of Cancer. 13:3477-3484
Autor:
Toshifumi Yamaguchi, Motoki Yoshida, Hisato Kawakami, Takayuki Kii, Hiroko Hasegawa, Takahiro Miyamoto, Tetsuji Terazawa, Fukutaro Shimamoto, Masayoshi Yasui, Daisuke Sakai, Toshio Shimokawa, Yukinori Kurokawa, Masahiro Goto, Taroh Satoh
Publikováno v:
Gastrointest Tumors
Introduction: Previous prospective studies suggest that the sequential use of cytotoxic agents, such as oxaliplatin, in patients with metastatic colorectal cancer (mCRC) has the potential to improve prognosis and maintain quality of life than combina
Autor:
EIKI YAMASAKI, FUKUTARO SHIMAMOTO, HIROKI NISHIKAWA, MASAHIRO GOTO, MITSUHIKO IWAMOTO, KOSEI KIMURA, AKIRA UKIMURA, NAOFUMI OOSAKA, KOHEI TANIGUCHI, FUMIHITO ONO, TETSUJI TERAZAWA, TOSHIFUMI YAMAGUCHI, KEN ASAISHI, TAKAKO IKEGAMI, KAZUHISA UCHIYAMA, SHIRO NAKAMURA, KAZUHIDE HIGUCHI
Publikováno v:
In Vivo
Background/Aim: To prospectively evaluate the efficacy and safety of the BNT162b2 vaccine in solid cancer patients undergoing systemic chemotherapy (n=63). Patients and Methods: COVID-19 anti-spike protein antibody levels were measured before the fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c481764c204061fd17818e0a98536c69
https://europepmc.org/articles/PMC9677789/
https://europepmc.org/articles/PMC9677789/
Autor:
Ryo Tanaka, Toshifumi Yamaguchi, Narikazu Boku, Kei Hosoda, Kazuhiro Nishikawa, Hitoshi Katai, Manabu Ohashi, Takahiro Kinoshita, Naoki Kakihara, Tatsuya Yamada, Hisayuki Matsushita, Atsuo Takashima, Masaki Aizawa, Kengo Nagashima, Masanori Terashima, Shusuke Haruta, Taroh Satoh, Yasuhiro Yuasa, Gen Yunome, Koshiro Ishiyama, Takeo Fukagawa
Publikováno v:
Gastric Cancer. 24:701-709
Gastric cancer (GC) patients with peritoneal metastasis are defined as stage IV in the Japanese classification of GC. For patients with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) and/or localized peritoneal metastasis